Alyeska Investment Group’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Alyeska Investment Group’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-595,553	Closed	-$13.7M	–	957
2020 Q4	$13.7M	Buy	+595,553	New	+$7.55M	0.19%	162

Alyeska Investment Group's PRVL Position: Q1 2021 in Review

Alyeska Investment Group sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 595,553 shares — an estimated $13.7M sold.

Alyeska Investment Group first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $13.7M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Alyeska Investment Group reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Alyeska Investment Group sold 595,553 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $13.7M.
Alyeska Investment Group first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Alyeska Investment Group's Prevail Therapeutics Inc. Common Stock position peaked at $13.7M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Alyeska Investment Group's 13F filing for Q1 2021, filed 17 May 2021.